AMLN Financial Facts
Total revenues: 153.69MNet product sales: 150.59M
See Full Income Statement
Accumulated other comprehensive loss: 4K
Convertible senior notes: 503.27M
See Full Balance Sheet
Earnings History for Amylin Pharmaceuticals, Inc. (AMLN)
|
Expand Research on AMLN
| Next EPS Date | 7/25/12 *Est. | EPS Growth Rate | +4.2% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -945.0% | Revenue Growth Rate | +0.7% *Last Qtr. |
| Average % Move 1-Wk after EPS | +0.5% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2/6/12  |
 |
Q411 | -$3.15 | -$0.08 | -$3.07 | $164.9M | $163.64M | N/A / N/A | N/A | +85.7% | Details |
| 7/26/11 |
|
Q211 | -$0.21 | -$0.18 | -$0.03 | $158.07M | $157.72M | N/A / N/A | N/A | +132.9% | Details |
| 10/19/11 |
|
Q311 | -$0.07 | -$0.15 | +$0.08 | $155.1M | $166.39M | N/A / N/A | N/A | +200.8% | Details |
| 4/26/12 |
|
Q112 | -$0.23 | -$0.29 | +$0.06 | $153.7M | $161.66M | N/A / N/A | N/A | +18.2% | Details |
| 4/18/11 |
|
Q111 | -$0.24 | -$0.23 | -$0.01 | $152.7M | $156.73M | N/A / N/A | N/A | +136.7% | Details |
| 11/4/10 |
|
Q310 | -$0.35 | -$0.35 | $0.00 | N/A | N/A | N/A / N/A | N/A | +144.1% | Details |
